Cinacalcet HCl: A novel therapeutic for hyperparathyroidism

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 3, 2005, Pages 441-452

  de Francisco, Angel L M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Calcimimetics; Calcium sensing receptor; Chronic kidney disease; End stage renal disease; Parathyroid carcinoma; Parathyroid hormone; Phosphate binders; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALUMINUM; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM SENSING RECEPTOR; CINACALCET; FLECAINIDE; LANTHANUM CARBONATE; PANTOPRAZOLE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; PROTON PUMP INHIBITOR; SEVELAMER; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VINBLASTINE; VITAMIN D DERIVATIVE;

ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; FATIGUE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; MORTALITY; MYALGIA; NAUSEA; NONHUMAN; PARATHYROID CARCINOMA; PARATHYROID CELL; PARESTHESIA; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; RECEPTOR SENSITIVITY; REVIEW; SECONDARY HYPERPARATHYROIDISM; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

CALCITRIOL; CALCIUM; HUMANS; HYPERPARATHYROIDISM; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RECEPTORS, CALCIUM-SENSING;

EID: 17144392965     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.3.441     Document Type: Review

References (106)

1. WEZEMAN FH, KUETTNER KE, HORTON JE: Morphology of osteoclasts in resorbing fetal rat bone explants: effects of PTH and AIF in vitro. Anat. Rec. (1979) 194(3):311-323.
2. RAISZ LG, LORENZO J, GWOREK S, KREAM B, ROSENBLATT M: Comparison of the effects of a potent synthetic analog of bovine parathyroid hormone with native bPTH-(1-84) and synthetic bPTH-(1-34) on bone resorption and collagen synthesis. Calcif. Tissue Int. (1979) 29(3):215-218.
3. BOURDEAU JE, LAU K: Effects of parathyroid hormone on cytosolic free calcium concentration in individual rabbit connecting tubules. J. Clin. Invest. (1989) 83(2):373-379.
4. BA J, BROWN D, FRIEDMAN PA: Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule phosphate transport. Am. J. Physiol. Renal Physiol. (2003) 285(6):F1233-F1243.
5. SHANE E: Clinical review 122: parathyroid carcinoma. J. Clin. Endocrinol. Metab. (2001) 86(2):485-493.
6. BROWN EM, GAMBA G, RICCARDI D et al.: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature (1993) 366(6455):575-580.
7. 2+ and a positive allosteric modulator. J. Biol. Chem. (2002) 277(48):46622-46631.
8. BOVER J, JARA A, TRINIDAD P, RODRIGUEZ M, FELSENFELD AJ: Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus. Bone (1999) 25 3):279-285.
9. MALMAEUS J, GRIMELIUS L, JOHANSSON H, AKERSTROM G, LJUNGHALL S: Parathyroid pathology in hyperparathyroidism secondary to chronic renal failure. Scand. J. Urol. Nephrol. (1984) 18(2):157-166.
10. MALBERTI F, FARINA M, IMBASCIATI E: The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol. Dial. Transplant. (1999) 14(10):2398-2406.
11. GOODMAN WG, VELDHUIS JD, BELIN TR et al.: Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. (1998) 83(8):2765-2772.
12. NAVEH-MANY T, SILVER J: Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J. Clin. Invest. (1990) 86(4):1313-1319.
13. SILVER J, RUSSELL J, SHERWOOD LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc. Natl. Acad. Sci. USA (1985) 82(12):4270-4273.
14. MOALLEM E, KILAV R, SILVER J, NAVEH-MANY T: RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J. Biol. Chem. (1998) 273 9):5253-5259.
15. KILAV R, SILVER J, NAVEH-MANY T: Parathyroid hormone gene expression in hypophosphatemic rats. J. Clin. Invest. (1995) 96 1):327-333.
16. BROWN AJ, FINCH J, TAKAHASHI F, SLATOPOLSKY E: Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. J. Am. Soc. Nephrol. (2000) 11(11):2088-2094.
17. BROOKMAN JJ, FARROW SM, NICHOLSON L, O'RIORDAN JL, HENDY GN: Regulation by calcium of parathyroid hormone mRNA in cultured parathyroid tissue. J. Bone Miner. Res. (1986) 1(6):529-537.
18. BLOCK GA, KLASSEN PS, LAZARUS JM et al.: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15(8):2208-2218.
19. RAGGI P, BOULAY A, CHASAN-TABER S et al.: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J. Am. Coll. Cardiol. (2002) 39(4):695-701.
20. GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2000) 342 20):1478-1483.
21. HRUSKA KA, TEITELBAUM SL: Renal osteodystrophy. N. Engl. J. Med. (1995) 333(3):166-174.
22. NATIONAL KIDNEY FOUNDATION: Bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(4 Suppl. 3):1-201.
23. KIM J, PISONI RL, DANESE MD et al.: Achievement of proposed NKF-K/DOQI bone metabolism and disease guidelines: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). J. Am. Soc. Nephrol. (2003) 14:269A-270A.
24. TAN AU Jr, LEVINE BS, MAZESS RB et al.: Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. (1997) 51(1):317-323.
25. GALLIENI M, BRANCACCIO D, PADOVESE P et al.: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int. (1992) 42(5):1191-1198.
26. LLACH F, KESHAV G, GOLDBLAT MV et al.: Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am. J. Kidney Dis. (1998) 32(2 Suppl. 2):S48-S54.
27. MARTIN KJ, GONZALEZ E, LINDBERG JS et al.: Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am. J. Kidney Dis. (2001) 38(5 Suppl. 5):S57-S63.
28. SLATOPOLSKY E, FINCH J, RITTER C, TAKAHASHI F: Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am. J. Kidney Dis. (1998) 32 2 Suppl. 2):S40-S47.
29. SLATOPOLSKY E, COZZOLINO M, FINCH JL: Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int. (2002) 62 4):1277-1284.
30. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31(4):607-617.
31. GOODMAN WG: Importance of hyperphosphataemia in the cardio-renal axis. Nephrol. Dial. Transplant. (2004) 19 Suppl. 1):i4-i8.
32. MORINIERE P, ROUSSEL A, TAHIRI Y et al.: Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc. Eur. Dial. Transplant Assoc. (1983) 19:784-787.
33. ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis encephalopathy syndrome. Possible aluminum intoxication. N. Engl. J. Med. (1976) 294(4):184-188.
34. HODSMAN AB, SHERRARD DJ, ALFREY AC et al.: Bone aluminum and histomorphometric features of renal osteodystrophy. J. Clin. Endocrinol. Metab. (1982) 54(3):539-546.
35. TZANNO-MARTINS C, AZEVEDO LS, ORII N et al.: The role of experimental chronic renal failure and aluminium intoxication in cellular immune response. Nephrol. Dial. Transplant. (1996) 11 3):474-480.
36. BLEYER AJ, BURKE SK, DILLON M et al.: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. (1999) 33(4):694-701.
37. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. (1986) 315(3):157-161.
38. HERVAS JG, PRADOS D, CEREZO S: Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney Int. Suppl. (2003) 85:S69-S72.
39. MCINTYRE CW, PATEL V, TAYLOR GS, FLUCK RJ: A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol. Dial. Transplant. (2002) 17 9):1643-1648.
40. SLATOPOLSKY EA, BURKE SK, DILLON MA: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. (1999) 55(1):299-307.
41. CHERTOW GM, BURKE SK, DILLON MA, SLATOPOLSKY E: Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol. Dial. Transplant. (1999) 14(12):2907-2914.
42. QUNIBI WY, HOOTKINS RE, MCDOWELL LL et al.: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. (2004) 65 5):1914-1926.
43. COMPSTON JE, HORTON LW: Oral 25-hydroxyvitain D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology (1978) 74(5 Pt 1):900-902.
44. FOURNIER A, OPRISIU R, ALBU AT et al.: The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients. Am. J. Kidney Dis. (2000) 35(6):1248-1250.
45. HOOGWERF BJ, HIBBARD DM, HUNNINGHAKE DB: Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J. Lab. Clin. Med. (1992) 119(4):407-411.
46. ISMAIL F, CORDER CN, EPSTEIN S, BARBI G, THOMAS S: Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin. Ther. (1990) 12 5):427-430.
47. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62(1):245-252.
48. GHAZALI A, FARDELLONE P, PRUNA A et al.: Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int. (1999) 55 6):2169-2177.
49. JOY MS, FINN WF: Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. (2003) 42(1):96-107.
50. D'HAESE PC, SPASOVSKI GB, SIKOLE A et al.: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. Suppl. (2003) 85:S73-S78.
51. CANAVESE C, MEREU C, NORDIO M, SABBIONI E, AIME S: Where have all the lanthanum salts gone, long time passing? Kidney Int. (2003) 64(6):2327-2328.
52. MALLUCHE HH, FAUGERE M-C, WANG G, DAMMENT SJP, WEBSTER I: No Evidence of Osteomalacia in Dialysis Patients Treated with Lanthanum Carbonate up to 5 Years. J. Am. Soc. Nephrol. 15:270A.
53. JOFRE R, LOPEZ GOMEZ JM, MENARGUEZ J et al.: Parathyroidectomy: whom and when? Kidney Int. Suppl. (2003) 85 S97-S100.
54. DE FRANCISCO AL, FRESNEDO GF, RODRIGO E et al.: Parathyroidectomy in dialysis patients. Kidney Int. Suppl. (2002) 80:161-166.
55. GAGNE ER, URENA P, LEITE-SILVA S et al.: Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J. Am. Soc. Nephrol. (1992) 3(4):1008-1017.
56. NEMETH EF, FOX J: Calcimimetic Compounds: a Direct Approach to Controlling Plasma Levels of Parathyroid Hormone in Hyperparathyroidism. Trends Endocrinol. Metab. (1999) 10 2):66-71.
57. KESSLER A, FAURE H, PETREL C et al.: N(2)-benzyl-N(1)-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg. Med. Chem. Lett. (2004) 14(12):3345-3349.
58. FOX J, LOWE SH, CONKLIN RL, PETTY BA, NEMETH EF: Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J. Pharmacol. Exp. Ther. (1999) 290(2):480-486.
59. NEMETH EF, STEFFEY ME, HAMMERLAND LG et al.: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. USA (1998) 95 7):4040-4045.
60. WADA M, ISHII H, FURUYA Y et al.: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. (1998) 53 2):448-453.
61. WADA M, NAGANO N, FURUYA Y et al.: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. (2000) 57(1):50-58.
62. ANTONSEN JE, SHERRARD DJ, ANDRESS DL: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int. (1998) 53 1):223-227.
63. GOODMAN WG, FRAZAO JM, GOODKIN DA et al.: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. (2000) 58 1):436-445.
64. GOODMAN WG, HLADIK GA, TURNER SA et al.: The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. (2002) 13(4):1017-1024.
65. QUARLES LD, SHERRARD DJ, ADLER S et al.: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J. Am. Soc. Nephrol. (2003) 14(3):575-583.
66. HARRIS R, PADHI D, SALFI M et al.: Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Daily Administration of Cinacalcet HCl up to 300 mg in Chronic Kidney Disease (CKD) Patients on Hemodialysis (HD). J. Am. Soc. Nephrol. (2003) 14:462A.
67. PADHI D, HARRIS R, SALFI M et al.: The Pharmacokinetics of Cinacalcet HCl are not altered by renal impairment or mode of renal replacement therapy. Nephrol. Dial. Transplant. (2003) 18 Suppl. 4):150.
68. PADHI D, HARRIS R, SALFI M et al.: Cinacalcet HCl absorption in study subjects is not affected by coadministration of medications commonly prescribed to chronic kidney disease (CKD) patients (pantoprazole, sevelamer HCl, and calcium carbonate. J. Am. Soc. Nephrol. (2003) 14:461A.
69. Sensipar™ (cinacalcet HCl) tablets prescribing information. Sensipar, Amgen, Inc., USA (2004).
70. LINDBERG JS, MOE SM, GOODMAN WG et al.: The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. (2003) 63(1):248-254.
71. BLOCK GA, MARTIN KJ, DE FRANCISCO AL et al.: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. (2004) 350(15):1516-1525.
72. MOE SM, CHERTOW GM, COBURN JW et al.: Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. (2005) 67(2):760-771.
73. STERRETT JR, STROM J, STUMMVOLL HK et al.: Long-term treatment of secondary hyperparathyroidism (HPT) with cinacalcet HCl (SensiparTM) in patients receiving dialysis. J. Am. Soc. Nephrol. (2004) 15:275A.
74. MOE SM, SPRAGUE SM, CUNNINGHAM J et al.: Long-term Treatment of Secondary Hyperparathyroidism (HPT) with the Calcimimetic Cinacalcet HCl. J. Am. Soc. Nephrol. (2003) 14:463A + poster.
75. SPRAGUE SM, NICOLINI M, EVENEPOEL P et al.: Maintenance of NKF-K/DOQITM Goals for Parathyroid Hormone and Ca × P with Cinacalcet HCl. J. Am. Soc. Nephrol. (2004) 15:514A-515A.
76. GOODMAN WG, DE FRANCISCO ALM, MOE SM et al.: Cinacalcet HCl (SensiparTM) is an Effective Treatment for Secondary Hyperparathyroidism (HPT) in CKD Patients on Dialysis. J. Am. Soc. Nephrol. (2004) 15:280A.
77. MITTMAN N, FINKELSTEIN F, CULLETON B et al.: Cinacalcet HCl (SensiparTM) for the Management of Secondary Hyperparathyroidism (HPT) in Patients Receiving Peritoneal Dialysis (PD). J. Am. Soc. Nephrol. (2004) 15:280A.
78. CHERTOW GM, CORPIER C, ZEIG S et al.: Preliminary Results from TARGET: Treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalcet. J. Am. Soc. Nephrol. (2004) 15:863A.
79. REED J, KEIGHTLEY G, BLUMENTHAL S et al.: The CONTROL STUDY: Enhanced Achievement of NKF-K/DOQITM Bone Metabolism and Disease Targets Using Cinacalcet HCl (Sensipar™). J. Am. Soc. Nephrol. (2004) 15:280A-281A.
80. SHOBACK DM, BILEZIKIAN JP, TURNER SA et al.: The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. (2003) 88 12):5644-5649.
81. PEACOCK M, BILEZIKIAN JP, KLASSEN PS et al.: Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism. J. Clin. Endocrinol. Metab. (2005) 90 1):135-141.
82. FRAKER DL: Primary Hyperparathyroidism. In: Cancer Principles & Practice of Oncology 6th edition. DeVita VT, Hellman S, Rosenberg SA (Eds.) Lippincott Williams & Wilkins, Philadelphia, USA (2001):1763-1770.
83. HUNDAHL SA, FLEMING ID, FREMGEN AM, MENCK HR: Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer (1999) 86(3):538-544.
84. UDELSMAN R: Surgery in primary hyperparathyroidism: the patient without previous neck surgery. J. Bone Miner. Res. (2002) 17(Suppl. 2):N126-N132.
85. SILVERBERG SJ, FAIMAN C, BILEZIKIAN JP et al.: The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTX. J. Bone Miner. Res. (2003) 18:S171.
86. PEACOCK M, BILEZIKIAN JP, KLASSEN PS et al.: Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. (2005) 90 1):135-141.
87. CUNNINGHAM J, CHERTOW G, GOODMAN W et al.: The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalization, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT). Abstracts XLI Congress of the ERA/EDTA. (2004) 219.
88. COLLOTON M, SHATZEN E, MILLER G et al.: Cinacalcet Hcl Attenuates Parathyroid Hyperplasia In A Rat Model Of Secondary Hyperparathyroidism. Kidney Int. (2005) 67:467-476.
89. MARTIN D, COLLOTON M, CATTLEY R, SHATZEN E, LACEY D: 1,25-Dihydroxyvitamin D3 but Not Cinacalcet HCl Treatment Mediates Aortic Mineralization in a Rat Model of Secondary Hyperparathyroidism. J. Am. Soc. Nephrol. (2003) 14(Abstracts Issue):693A.
90. MARTIN D, COLLOTON M, SHATZEN E: Efficacy of cinacalcet HCl is independent of dietary phosphorus intake in a rodent model of chronic kidney disease (CKD). J. Am. Soc. Nephrol. (2004) 15:273A.
91. PITTS TO, PIRAINO BH, MITRO R et al.: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J. Clin. Endocrinol. Metab. (1988) 67(5):876-881.
92. REICHEL H, DEIBERT B, SCHMIDT-GAYK H, RITZ E: Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol. Dial. Transplant. (1991) 6(3):162-169.
93. CHONCHOL M, KOPYT N, HERMAN J et al.: Cinacalcet HCl reduces parathyroid hormone (PTH) in patients with stage 3 and 4 chronic kidney disease (CKD). Am. J. Kidney Dis. (2004) 43(4):A19.
94. COBURN JW, CHARYTAN C, CHONCHOL M et al.: Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) not yet receiving dialysis. J. Am. Soc. Nephrol. (2003) 14:460A.
95. BERNHEIM J, TOURAINE JL, DAVID L, FAIVRE JM, TRAEGER J: Evolution of secondary hyperparathyroidism after renal transplantation. Nephron. (1976) 16(5):381-387.
96. TRABULUS S, APAYDIN S, ALTIPARMAK MR et al.: Osteoporosis after renal transplantation. Nefrologia (2003) 23 Suppl. 2):127-130.
97. VAUTOUR LM, MELTON LJ III, CLARKE BL et al.: Long-term fracture risk following renal transplantation: a population-based study. Osteoporos. Int. (2004) 15(2):160-167.
98. ROE SD, PORTER CJ, GODBER IM, HOSKING DJ, CASSIDY MJ: Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism. Osteoporos. Int. (2005) 16 2):142-148.
99. WILHELM SM, LEE J, PRINZ RA: Major depression due to primary hyperparathyroidism: a frequent and correctable disorder. Am. Surg. (2004) 70(2):175-179.
100. REGAL M, PARAMO C, LUNA CR et al.: Coexistence of primary hyperparathyroidism and thyroid disease. J. Endocrinol. Invest. (1999) 22(3):191-197.
101. PICKARD AL, GRIDLEY G, MELLEMKJAE L et al.: Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer (2002) 95(8):1611-1617.
102. KHOSLA S, MELTON LJ III, WERMERS RA et al.: Primary hyperparathyroidism and the risk of fracture: a population-based study. J. Bone Miner. Res. (1999) 14(10):1700-1707.
103. CUNNINGHAM J: Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol. Dial. Transplant. (2004) 19(Suppl. 5):V9-V14.
104. FROLIK CA, BLACK EC, CAIN RL et al.: Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone (2003) 33(3):372-379.
105. GOGUSEV J, DUCHAMBON P, HORY B et al.: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. (1997) 51(1):328-336.
106. MIZOBUCHI M, HATAMURA I, OGATA H et al.: Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J. Am. Soc. Nephrol. (2004) 15(10):2579-2587.